Business Health

Women’s Healthcare Market Size, Share, COVID-19 Impact and Analysis 2021- Business Strategies, Future Growth, Demand and Forecast Report 2027: SPER Market Research

April 10, 2023
varsha.sper

The Women’s Healthcare Market is expected to grow at a CAGR of ~9.78% from 2021 to reach USD 19.8 billion by 2027. The global women’s healthcare market is expected to grow at a CAGR of ~9.78% from 2021 to reach USD 19.8 billion by 2027. The growth is mainly ascribed by the prevalence of chronic health disorders among women, government initiatives aimed to control population and prevention of unwanted pregnancies and R&D in women’s health products.

Women’s Healthcare Market Overview (2021-2027)

  • Forecast CAGR (2021-2027): 9.78%
  • Forecast Market Size (2027): 19.8 billion

The global women’s healthcare market study provides market data for-by drug (EVISTA, XGEVA, Prolia, Mirena, Zometa, Reclast/Aclasta, Minastrin 24 Fe, NuvaRing, FORTEO, Premarin, ACTONEL and ORTHO TRI-CY LO (28), by application (hormonal infertility, postmenopausal osteoporosis, endometriosis, contraceptives, menopause, polycystic ovary syndrome, and other applications). The study also evaluates industry competitors and analyses the market at a regional and country level.

Request For Free Sample Report @ https://www.sperresearch.com/report-store/Women-Health-Care.aspx?sample=1

Women’s Healthcare Market Key Players:

This study provides market data by competitive landscape, revenue analysis, market segments and detailed analysis of key market players such as: Bayer AG (Germany), Allergan (Dublin), Merck & Co. (US), Pfizer Inc. (US), Amgen (US), Agile Therapeutics Inc. (US), Ferring Pharmaceuticals (US), Mylan N.V. (US), Lupin (India), Blairex Laboratories (US), Apothecus Pharmaceutical (US), Eli Lilly And Company (US), Novartis AG (Switzerland), Johnson & Johnson (US).

Women’s Healthcare Market Key Segments Covered

The SPER Market Research report seeks to give market dynamics, demand, and supply forecasts for the years up to 2027. This report contains statistics on product type segment growth estimates and forecasts.

By Drug:

  • EVISTA
  • XGEVA
  • Prolia
  • Mirena
  • Zometa
  • Reclast/Aclasta
  • Minastrin 24 Fe
  • NuvaRing
  • FORTEO
  • Premarin
  • ACTONEL
  • ORTHO TRI-CY LO

By Application:

  • Hormonal Infertility
  • Postmenopausal Osteoporosis
  • Endometriosis
  • Contraceptives
  • Menopause
  • Polycystic Ovary Syndrome
  • Other

By Region:

  • North America
  • Europe
  • Asia-Pacific

North America accounted for the largest share of the global women’s healthcare market due to the prevalence of poly cystic ovary syndrome & post-menopausal osteoporosis in the population, increasing expenditure on women’s health by governments. On the other hand, APAC is expected to grow at highest CAGR. The growth is mainly driven by rising awareness, prevalence of disorders such as infertility, osteoarthritis and other related diseases in women.

For More Information, refer to below link:-

Women’s Healthcare Market Future Outlook

Related Reports:

Digital Telepathology Market Size- By Type, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Monkeypox Treatment Market Size- By Treatment, By Product Type, By Dosage Form, By Route of Administration, By Age, By Gender, By Prescription Type, By End User – Regional Outlook, Competitive Strategies and Segment Forecast to 2032

Follow Us –

LinkedIn | Instagram | Facebook | Twitter

Contact Us:

Sara Lopes, Business Consultant – U.S.A.

SPER Market Research

enquiries@sperresearch.com

+1-347-460-2899